VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M

Author: Benzinga Newsdesk | March 25, 2024 04:11pm

Financial Highlights

• Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022.
• Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year.
• Received $13.0 million in milestone payments from Heska Corporation in December 2023.
• Net cash used in operating activities was $18.1 million for the full year.

Event:	VolitionRx Limited Fourth Quarter and Full Year 2023 Earnings and Business Update Conference Call
Date:	Tuesday, March 26, 2024
Time:	8:30 a.m. U.S. Eastern Time
U.S. & Canada Dial-in:	1-877-407-9716 (toll free)
U.K. Dial-in:	0 800 756 3429 (toll free)
Toll/International:	1-201-493-6779
Conference ID:	13745274

Cameron Reynolds, President and Group Chief Executive Officer of Volition, will host the call along with Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, Dr. Andrew Retter, Chief Medical Officer of Volition and Louise Batchelor, Group Chief Marketing & Communications Officer. The call will provide an update on important events which have taken place in the fourth quarter and full year of 2023 and upcoming milestones.

A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at https://ir.volition.com. In addition, a telephone replay of the call will be available until April 9, 2024. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13745274.

Posted In: VNRX